Emerging clinical evidence suggests that Novera Retatrutide, a dual-action therapy from Novo Nordisk, could offer a significant step in weight control. Differing from many existing options, Retatrutide impacts both GLP-1 and GIP, potentially leading to greater losses in fat and better outcomes fo